Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Platinum Sensitive Ovarian Cancer Clear all
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

NCT01995188
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Bevacizumab, Carboplatin, DNIB0600A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Jul 23, 2026, 4:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

NCT02759588
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
Interventions
Olvi-Vec, Platinum-doublet with or without bevacizumab
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Newport Beach, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 23, 2026, 4:21 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
33
States / cities
Birmingham, Alabama • Anchorage, Alaska • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 4:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

NCT01035658
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions
Pazopanib, Doxil
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Fort Myers, Florida • Orlando, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jul 23, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

NCT01891344
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Oral rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
36
States / cities
Anchorage, Alaska • Tucson, Arizona • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Jul 23, 2026, 4:21 PM EDT
Terminated Phase 2 Interventional

Study of XL999 in Patients With Previously Treated Ovarian Cancer

NCT00277290
View directory record Official record
Conditions
Ovarian Cancer
Interventions
XL999
Drug
Lead sponsor
Symphony Evolution, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
9
States / cities
Greenbrae, California • Port Saint Lucie, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2010 · Synced Jul 23, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer

NCT00719212
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
AMG 479
Biological
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
16
States / cities
Bakersfield, California • Fullerton, California • La Verne, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Jul 23, 2026, 4:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

NCT01133756
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Lenvatinib, Carboplatin, Gemcitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 23, 2026, 4:21 PM EDT
Completed Phase 2 Interventional

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT01767675
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer
Interventions
Secondary Cytoreductive Surgery, Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC), platinum-based systemic chemotherapy postoperatively
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
11
States / cities
Hartford, Connecticut • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 23, 2026, 4:21 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT03079687
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Duarte, California • Newport Beach, California • Roseville, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Jul 23, 2026, 4:21 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

NCT05231122
View directory record Official record
Conditions
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
Interventions
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Buffalo, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 23, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

NCT02953457
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Olaparib, Tremelimumab
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 23, 2026, 4:21 PM EDT
Completed Phase 2 Interventional

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

NCT00325351
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Sagopilone (ZK 219477) + carboplatin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
14
States / cities
Tucson, Arizona • Little Rock, Arkansas • Bakersfield, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jul 23, 2026, 4:21 PM EDT
Terminated Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer

NCT01016054
View directory record Official record
Conditions
Carcinoma, Ovarian Cancer, Ovarian Diseases, Ovarian Neoplasms
Interventions
AGS-8M4, Pegylated liposomal doxorubicin (PLD), gemcitabine, carboplatin
Biological · Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Jul 23, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Results available

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

NCT03704467
View directory record Official record
Conditions
Ovarian Cancer
Interventions
M6620, Avelumab, Carboplatin
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
7
States / cities
Greenbrae, California • Stamford, Connecticut • Saginaw, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jul 23, 2026, 4:21 PM EDT
Completed Phase 2 Interventional

Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00086892
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cetuximab, carboplatin
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 64 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 23, 2026, 4:21 PM EDT
Recruiting Phase 1 Interventional

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

NCT05942300
View directory record Official record
Conditions
Recurrent Ovarian Cancer
Interventions
CPI-0209, carboplatin
Drug
Lead sponsor
Lan Coffman
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 4:21 PM EDT
Active, not recruiting Phase 1 Interventional

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270
View directory record Official record
Conditions
Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 4:21 PM EDT
Terminated Phase 2 Interventional Results available

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

NCT02978222
View directory record Official record
Conditions
Platinum Sensitive Ovarian Cancer, Ovarian Cancer
Interventions
FRα peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF) Alone
Biological · Drug
Lead sponsor
Marker Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Jul 23, 2026, 4:21 PM EDT
Completed Phase 2 Interventional

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

NCT00466986
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Abraxane
Drug
Lead sponsor
Southeastern Gynecologic Oncology
Other
Eligibility
Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Jul 23, 2026, 4:21 PM EDT
Completed Phase 1 Interventional

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

NCT02020707
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, Cervical Carcinosarcoma, Cervical Squamous Cell Carcinoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Squamous Cell Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Female Reproductive System Neoplasm, Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Epithelial Tumor, Malignant Ovarian Mucinous Tumor, Malignant Peritoneal Neoplasm, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Unresectable Melanoma, Uterine Corpus Carcinosarcoma
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel, Pharmacological Study
Biological · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Jul 23, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

NCT02983799
View directory record Official record
Conditions
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions
OLAPARIB
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
35
States / cities
Anchorage, Alaska • La Jolla, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Jul 23, 2026, 4:21 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

NCT07024784
View directory record Official record
Conditions
Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
Interventions
IMGN151, Carboplatin, Bevacizumab, Olaparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Teaneck, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 23, 2026, 4:21 PM EDT
Terminated Phase 2 Interventional Results available

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

NCT04377087
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib
Drug
Lead sponsor
Sarah E Taylor
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Jul 23, 2026, 4:21 PM EDT